biostudies-literatureMoscoso ANCATS NIH HHSNIBIB NIH HHSEuropean Research CouncilNIA NIH HHSNCRR NIH HHSNIAID NIH HHSRRD VANIMH NIH HHSNIDCD NIH HHSNINDS NIH HHSWellcome TrustNIH HHS229-242https://www.ebi.ac.uk/biostudies/studies/S-EPMC12848857biostudies-literatureUnknown334(3)<h4>Importance</h4>Tau positron emission tomography (PET) allows in vivo detection of neurofibrillary tangles, a core neuropathologic feature of Alzheimer disease (AD).<h4>Objective</h4>To provide estimates of the frequency of tau PET positivity and its associated risk of clinical outcomes.<h4>Design, setting, and participants</h4>Longitudinal study using data pooled from 21 cohorts, comprising a convenience sample of 6514 participants from 13 countries, collected between January 2013 and June 2024. Cognitively unimpaired individuals and patients with a clinical diagnosis of mild cognitive impairment (MCI), AD dementia, or other neurodegenerative disorders were included.<h4>Exposures</h4>Tau PET with flortaucipir F 18, amyloid-β (Aβ) PET, and clinical examinations. Tau PET scans were visuaJAMAFrequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.PMC12848857R01 AG058724P30 AG028283R56 AG045571P30 AG053760U01 AG057195R01 AG079142P50 AG047266P20 AG068053R35 AG072362P30 AG066444P30 AG019610R01 AG062276P30 AG072958P30 AG072959P50 AG047270P30 AG066546R01 AG056031P01 AG036694P50 MH071616U19 NS120384U24 AG067418U24 RR021382R01 AG069453P30 AG072946P20 MH071616P01 AG003991P30 AG072947R01 AG052560P30 AG010133220258101096455P30 AG072931P20 AG068077R01 AG067781R01 DC008552P30 AG010129R01 NS075075R56 AG074321R01 AG054110R01 AG056531R01 AG019771R01 AG056258F30 AG067677P50 AG016574P30 AG066530P20 AG068082P50 AG016573R01 AG077444P30 AG062677P50 AG005142P30 AG066514P30 AG066515P30 AG066518P30 AG062715P30 AG066519R01 AG053993R01 AG043434R56 AG057195U19 AG073153R01 AG053509R01 AG081394R01 AG045571R01 AG061788R01 AG068338U19 AG063911P50 AG008702P30 AG062428P30 AG062421P30 AG062422R01 AG073235P30 AG010161P30 AG066506P30 AG066507UL1 TR000448I01 RX001534P30 AG066508P30 AG062429P30 AG066509R01 AG021910S10 OD026738P30 AG066511P30 AG066512U24 AG072122R01 AG083740P20 AG068024P30 AG013846P30 AG008017P50 AG033514U01 AG006786P30 AG072980R01 AG034570P50 AG047366P30 AG072975P30 AG066462P30 AG072976P30 AG072977R35 AG072262P30 AG072972P30 AG066468P30 AG072973R01 EB009352P30 AG072978P30 AG072979R01 AG079280P30 AG013854R01 AG055005I21 RX001381F31 AG067677P50 AG005136P30 AG035982P50 AG005133P30 NS098577U01 AG024904P01 AG026276Chhatwal JPPogossova GCrawford KGervais VBernard MLafaille-Magnan MEPoirier JAguiar PSpreng NCarrillo MOkonkwo ODeCarli CGunter JFrisoni GBFigurski MRiddle MFrenette JRogalski ECouture DHoge RMontine TTaylor-Reinwald LMathis CFonov VVogel JKat JHansson ONudelman KDuara RLabonte AYuschkevich PAMohammediyan BSepulcre JRioux PDage JToga ATullo SLois Gomez CGonzalez HFletcher EMathieu AKazazian CSilva-Rodriguez JMusiek ESeo SWSalloway SSchwarz CMiller GMalone IGatchel JCarrier CETurner RSTeigner EYu ENeu SPardilla-Delgado EQuiroz YKhachaturian ZJones DDrzezga ANeuhaus JNewell KJohnson KAConti CCheewakriengkrai LNir TMRisacher SLRajah NFerdinand FAppleby MBuckley RDadar MCoomans EMFrappier JDickerson BAisen PClanton TCamacho VAnthal ESoleimani-Meigooni DNCraft SKirby KMurray MEGrinberg LTRowe JBGuzman-Velez EDebacker CHammers DEloyan ADansereau CSoucy JPBrum WSBedetti CZimmerman CVachon-Presseau ERentz DMalpetti MSaint-Fort EFMulthaup GApostolova LGBrandt JBorowski BFockler JLandau SRaghavan SKukull WAOzlen HKoeppe RAAshford MJutten REl-Khoury RReynolds GChen YGreen RCReiman EMEvans ADuclair GOaoo KChen KTardif CNear JBarnes LDesautels RForoud TChen SRPetersen RCDufour MHergesheimer LDaoust LAFleisher AGagliardi GEisenberg MCuello CMasdeu JVeitch DBernhardt HNho KBarkun ASkylar-Scott ITheroux LTuwaig MFranklin EFarzin SRyan LRodriguez-Fonseca OGeddes MFaubert AMChoe MDauar-Tedeschi MMcSweeney MCoker GReid RNosheny RAdegoke OMadjar CChapleau MCourcot BSager MHonig LSRafii MMorris JRemz JFlenniken DSavard MJackson JSaykin AJvan Essen MMendez MMoore SAtri AJean GGessert DFaber KThompson PBreitner JDubuc SSylvain EOnyike CUMeyer POCollins LVemuri PFox NCShen LPruessner JTouroutoglou AClark DWolk DAGordon RTosun-Turgut DSenjem MBlacker DThal LKoeppe RJin CWan KO'Brien JTSilverberg NMasliah ESalazar JKnaack AShaffer EPizzola JGiles RFontaine DKostopoulos PGhetti BOssenkoppele RVila-Castelar CPage VIturia-Medina YJacobs HWalter SVerfaillie SKnopman DVenugopalan VJohnson ECBKramer JThangarajah MYun JCarmo LCairns NJToga AWPetkova MLegarde JMasterman DVilleneuve SLeoutsakos JMThomas RCabrera YPascoal TBenbouhoud FJones DTGaribotto VPerrin RJMayrand GJagust WJMahboubi PPrice JLaMontagne PJForoud TMYang HSRosa-Neto PGreco CTam APichet Binette ARaman RBohbot VSt-Onge FLeblond-Baccichet GGagne GScholl MPeretti DSperling RAPishnamazi MOrban PPerissinotti ATabrizi SHouseholder ESha SLee TKobe TForghanian-Arani AGauthier SToussaint PJBeckett LJack CRDay GSSalaciak ATaurone AGraff-Radford NRA Lie MJWang SAmariglio REMiron JVallee IGrothe MJLepage CMaltais JRBailly JWilmes KTremblay-Mercier JHo CHeeman FMathotaarachchi SMichaud DSchultz ADickerson BCNewbold-Fox HWeiner MWPotter WDucharme SDonovan NCostoya-Sanchez AKorecka MBeaudry THarvey DBellec PHudon LWard CWomack Kvan de Giessen EMNilsson NPicard CVannini PDas SChakravarty MMainta IGrant IEtienne PMaillet DKormos AFarrell MNair VRibaldi FLeppert ISchultz SPontecorvo MJLa Joie RRabinovici GDHsiao JKProkopiou PJahanshad NGu YTrojanowki JQDea DBischof GNMarshall GMorris JCDonohue MJimenez GWingo TSSmith SSmith RThomopoulos SIBoutin SPREVENT-AD Research Group, the Harvard Aging Brain Study, the LEADS Consortium, and the Alzheimer’s Disease Neuroimaging InitiativeTariot PMoscoso AMahar LShaw LMGonneaud JPolsinelli AKantarci KfalseFrequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.<h4>Importance</h4>Tau positron emission tomography (PET) allows in vivo detection of neurofibrillary tangles, a core neuropathologic feature of Alzheimer disease (AD).<h4>Objective</h4>To provide estimates of the frequency of tau PET positivity and its associated risk of clinical outcomes.<h4>Design, setting, and participants</h4>Longitudinal study using data pooled from 21 cohorts, comprising a convenience sample of 6514 participants from 13 countries, collected between January 2013 and June 2024. Cognitively unimpaired individuals and patients with a clinical diagnosis of mild cognitive impairment (MCI), AD dementia, or other neurodegenerative disorders were included.<h4>Exposures</h4>Tau PET with flortaucipir F 18, amyloid-β (Aβ) PET, and clinical examinations. Tau PET scans were visua2025-01-01T00:00:00Z2025 Jul2026-06-11T05:38:24.383Z2026-06-11T03:08:06.012ZS-EPMC128488574052265210.1001/jama.2025.7817